The latest price target for Maravai LifeSciences (NASDAQ:MRVI) was reported by Goldman Sachs on December 5, 2024. The analyst firm set a price target for $4.25 expecting MRVI to fall to within 12 months (a possible -24.51% downside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Maravai LifeSciences (NASDAQ:MRVI) was provided by Goldman Sachs, and Maravai LifeSciences downgraded their sell rating.

The last upgrade for Maravai LifeSciences Holdings Inc happened on December 12, 2023 when B of A Securities raised their price target to $8. B of A Securities previously had a neutral for Maravai LifeSciences Holdings Inc.

The last downgrade for Maravai LifeSciences Holdings Inc happened on December 5, 2024 when Goldman Sachs changed their price target from $7 to $4.25 for Maravai LifeSciences Holdings Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Maravai LifeSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Maravai LifeSciences was filed on December 5, 2024 so you should expect the next rating to be made available sometime around December 5, 2025.

While ratings are subjective and will change, the latest Maravai LifeSciences (MRVI) rating was a downgraded with a price target of $7.00 to $4.25. The current price Maravai LifeSciences (MRVI) is trading at is $5.63, which is out of the analyst’s predicted range.